



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/582,492	03/06/2002	Elizabeth S. Light	142/003/PCT	8768
23874	7590	11/15/2005	EXAMINER	
VENTANA MEDICAL SYSTEMS, INC. ATTENTION: LEGAL DEPARTMENT 1910 INNOVATION PARK DRIVE TUCSON, AZ 85755			SWITZER, JULIET CAROLINE	
			ART UNIT	PAPER NUMBER
			1634	
DATE MAILED: 11/15/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No. 09/582,492	Applicant(s) LIGHT ET AL.	
	Examiner Juliet C. Switzer	Art Unit 1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE *three* MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 09 September 2005.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1,3,7,17,19 and 22 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3,7,17,19 and 22 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/23/05 has been entered.

2. Applicant's amendments filed 9/23/05 have been entered. Claims 1, 3, 7, 17, 19, and 22 are pending. Claim 1 has been amended. Applicant's amendments and arguments have been thoroughly reviewed, but are not persuasive for the reasons that follow. Any rejections not reiterated in this action have been withdrawn. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

### ***Claim Rejections - 35 USC § 102***

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

4. Claims 1 and 17 are rejected under 35 U.S.C. 102(b) as being anticipated by Meijer *et al.* (WO 95/22626).

Art Unit: 1634

Meijer *et al.* teach a reagent for detecting human papillomavirus DNA comprising a plurality of DNA probes capable of specifically hybridizing to high-risk HPV DNA but not low-risk HPV DNA. In particular, Meijer *et al.* teach a mixture of probes specific for HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56, and 58, and that this mixture does not contain probes specific for a variety of “low risk” HPV types (p. 16, lines 15-23).

Thus, the reagent taught by Meijer *et al.* is considered to include a first genomic HPV DNA probe set that comprises a plurality of nucleic acid fragments that detectably hybridize to essentially the entire full length genomic sequence of each of the HPV types represented in the cocktail. For example, regarding HPV type 16, the oligonucleotide probes within the “cocktail” taught by Meijer *et al.* specific for HPV type 16 would be a plurality of fragments, since there would inherently be more than one copy of each probe in the solution, and these are would detectably hybridize to essentially the entire full length HPV type 16 genomic sequence, were the entire sequence in the solution. That is, if the full length sequence of HPV 16 were in a solution, the fragments taught by Meijer *et al.* would hybridize to this sequence, albeit the hybridization would only occur over a small portion of the sequence. The same is true for each of types (b)-(f) recited in claim 1.

With regard to claim 17, the probe cocktail taught by Meijer *et al.* and exemplified on page 30 of Meijer *et al.* would have inherently been within a container.

#### ***Claim Rejections - 35 USC § 103***

5. Claims 3 and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Meijer *et al.* in view of Orth *et al.* (US 5981173).

Art Unit: 1634

Meijer *et al.* teach a reagent for detecting human papillomavirus DNA comprising a plurality of DNA probes capable of specifically hybridizing to high-risk HPV DNA but not low-risk HPV DNA. In particular, Meijer *et al.* teach a mixture of probes specific for HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56, and 58, and that this mixture does not contain probes specific for a variety of “low risk” HPV types (p. 16, lines 15-23).

Thus, the reagent taught by Meijer *et al.* is considered to include a first genomic HPV DNA probe set that comprises a plurality of nucleic acid fragments that detectably hybridize to essentially the entire full length genomic sequence of each of the HPV types represented in the cocktail. For example, regarding HPV type 16, the oligonucleotide probes within the “cocktail” taught by Meijer *et al.* specific for HPV type 16 would be a plurality of fragments, since there would inherently be more than one copy of each probe in the solution, and these are would detectably hybridize to essentially the entire full length HPV type 16 genomic sequence, were the entire sequence in the solution. That is, if the full length sequence of HPV 16 were in a solution, the fragments taught by Meijer *et al.* would hybridize to this sequence, albeit the hybridization would only occur over a small portion of the sequence. The same is true for each of types (b)-(f) recited in claim 1, from which claim 3 depends. Meijer *et al.* further teach that it is advisable to add HPV 59 to the high risk reagent and suggest that the probe cocktail needs to be supplemented when new identified high risk HPVs are found (p. 16, line 26-p. 17, line 5).

With regard to claim 19, the probe cocktail taught by Meijer *et al.* and exemplified on page 30 of Meijer *et al.* would have inherently been within a container.

Meijer *et al.* do not teach a reagent that hybridizes to HPV types 68 and 70.

Art Unit: 1634

Orth *et al.* teach the genomes of HPV68 and HPV70 and teach that they were cloned from cervical interepithelial neoplasia (ABSTRACT, and throughout). Orth *et al.* teach oligonucleotide probes for the detection of HPV types 68 and 70 (Col. 3, lines 34-44) and teach that these probes can be used in combination with probes derived from other HPV (Col. 3, lines 54-56).

Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have included probes specific for HPV 68 and HPV 70 in the reagents taught by Meijer *et al.* The ordinary practitioner would have been motivated to include the probes to the additionally HPV types in order to follow the explicit guidance provided by Meijer *et al.* to include additional HPV probes for a more complete set of probes for detection of HPV that lead to high risk for the development of cancer.

6. Claims 7 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Meijer *et al.* in view of Bauer *et al.* (US 5639871).

Meijer *et al.* teach a reagent for detecting human papillomavirus DNA comprising a plurality of DNA probes capable of specifically hybridizing to high-risk HPV DNA but not low-risk HPV DNA. In particular, Meijer *et al.* teach a mixture of probes specific for HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56, and 58, and that this mixture does not contain probes specific for a variety of “low risk” HPV types (p. 16, lines 15-23).

Thus, the reagent taught by Meijer *et al.* is considered to include a first genomic HPV DNA probe set that comprises a plurality of nucleic acid fragments that detectably hybridize to essentially the entire full length genomic sequence of each of the HPV types represented in the cocktail. For example, regarding HPV type 16, the oligonucleotide probes within the “cocktail”

Art Unit: 1634

taught by Meijer et al. specific for HPV type 16 would be a plurality of fragments, since there would inherently be more than one copy of each probe in the solution, and these are would detectably hybridize to essentially the entire full length HPV type 16 genomic sequence, were the entire sequence in the solution. That is, if the full length sequence of HPV 16 were in a solution, the fragments taught by Meijer et al. would hybridize to this sequence, albeit the hybridization would only occur over a small portion of the sequence. The same is true for each of types (b)-(f) recited in claim 1, from which claim 7 depends. Meijer *et al.* further teach that it is advisable to add HPV 59 to the high risk reagent and suggest that the probe cocktail needs to be supplemented when new identified high risk HPVs are found (p. 16, line 26-p. 17, line 5).

With regard to claim 22, the probe cocktail taught by Meijer et al. and exemplified on page 30 of Meijer et al. would have inherently been within a container.

Meijer *et al.* do not teach a reagent having probes in the concentrations given in claim 7. However, the optimization of hybridization assays by determining ideal probe concentrations was routine in the prior art at the time the invention was made, as is exemplified by Bauer *et al.* who teach “The optimal ration and concentration of probe fragments to be used in the hybridization are determined empirically (Col. 51, lines 60-63).”

Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have experimented with different probe concentrations so as to arrive at an optimal concentration for the detection of HPV in a sample. It is well settled that routine optimization is not patentable, even if it results in significant improvements over the prior art. In support of this position, attention is directed to the decision in *In re Aller, Lacey, and Hall*, 105 USPQ 233 (CCPA 1955):

Art Unit: 1634

Normally, it is to be expected that a change in temperature, or in concentration, or in both, would be an unpatentable modification. Under some circumstances, however, changes such as these may impart patentability to a process if the particular ranges claimed produce a new and unexpected result which is different in kind and not merely in degree from the results of the prior art. In re Dreyfus, 22 C.C.P.A. (Patents) 830, 73 F.2d 931, 24 USPQ 52 ; In re Waite et al., 35 C.C.P.A. (Patents) 1117, 168 F.2d 104, 77 USPQ 586 . Such ranges are termed "critical" ranges, and the applicant has the burden of proving such criticality. In re Swenson et al., 30 C.C.P.A. (Patents) 809, 132 F.2d 1020, 56 USPQ 372 ; In re Scherl, 33 C.C.P.A. (Patents) 1193, 156 F.2d 72, 70 USPQ 204 . However, even though applicant's modification results in great improvement and utility over the prior art, it may still not be patentable if the modification was within the capabilities of one skilled in the art. In re Sola, 22 C.C.P.A. (Patents) 1313, 77 F.2d 627, 25 USPQ 433 ; In re Normann et al., 32 C.C.P.A. (Patents) 1248, 150 F.2d 708, 66 USPQ 308 ; In re Irmischer, 32 C.C.P.A. (Patents) 1259, 150 F.2d 705, 66 USPQ 314 . More particularly, where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation. In re Swain et al., 33 C.C.P.A. (Patents) 1250, 156 F.2d 239, 70 USPQ 412 ; Minnesota Mining and Mfg. Co. v. Coe, 69 App. D.C. 217, 99 F.2d 986, 38 USPQ 213 ; Allen et al. v. Coe, 77 App. D. C. 324, 135 F.2d 11, 57 USPQ 136. (Emphasis added)

For these reasons, the claimed invention is *prima facie* obvious.

7. Claims 1, 3, 17, and 19 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nuovo et al. (1995) in view of Cox et al. (Am. J. of Obstet. Gynecol., 1995, Vol. 172, p. 946-954).

Nuovo *et al.* teach a reagent for detecting human papillomavirus DNA in a cell sample comprising a plurality of genomic DNA probe sets, wherein each probe set comprises a plurality of nucleic acid fragments that detectably hybridize to essentially the entire full-length genomic sequence of HPV types 16 and 18, as well as a similar reagent that hybridizes to HPV types 31, 33, and 35. Nuovo *et al.* teach probe mixes provided by Digene that are made using the entire genome and that contain probes for these groups of HPV subtypes (p. 106, "Probe selection.").

Art Unit: 1634

With regard to claims 17 and 19, Nuovo *et al.* teach that they obtain these probes in kits from Digene Diagnostics, and these kits would inherently comprise containers containing the probes.

Nuovo *et al.* do not teach a reagent that comprises genomic probe sets that are fragments of essentially the full-length genomic sequence of all of the HPV types listed in claim 1.

Cox *et al.* teach a single reagent that comprises RNA probes to a group of high risk HPV types which includes types 16, 18, 31, 33, 35, 51, 45, 52, and 56 (p. 948). Cox *et al.* also teach separate assays to test for high risk HPV types 39 and 58 (p. 948), and suggest that the assay they used be expanded to include types 39 and 58 (p. 953, 2<sup>nd</sup> column).

It would have been *prima facie* obvious at the time the invention was made to have modified the reagents taught by Nuovo *et al.* so as to have provided a single reagent that includes nick-translated DNA probes to all of the types probed by Cox *et al.* One would have been motivated to provide such a mix in order to have provided a DNA probe cocktail that had the ability to detect many different known high risk HPV types in a hybridization assay analogous to that to that used by Cox *et al.* One would have been motivated to use DNA probes as opposed to RNA probes as taught by Cox *et al.* because DNA probes are more stable in solution than RNA probes which are more quickly degraded. With regard to the requirement that these probes “not detectably hybridize to the genomic sequence of a low-risk HPV type” this is considered to be a necessary property of the probe set taught by Nuovo *et al.* in view of Cox *et al.* since at very high stringency conditions such cross-hybridization would not be expected. Thus, in view of a secondary consideration, such as an unexpected result, the claimed invention is *prima facie* obvious.

Art Unit: 1634

With regard to claim 3, the cross-hybridization of the probes taught by Nuovo *et al.* in view of Cox *et al.* to the genomic sequences of HPV types 39, 45, 52, 56, 58, 59, 68, and 70 is an necessary property of the probe set. Some cross-hybridization of the full length probe cocktail taught by Nuovo *et al.* to these sequences could be expected under some stringency conditions. Notably, this is evidenced by the instant specification which teaches that full length nick translated genomic probe to HPV 18 hybridizes to 18, 39, 45, 56, 59, 68, and 70 and full length nick translated genomic probe to HPV 33 hybridizes to 16, 31, 33, 35, 45, 52, and 58.

### ***Double Patenting***

8. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned

Art Unit: 1634

with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

9. Claims 1, 3, 7, 17, 19, and 22 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-7 and 17-22 of copending Application No. 10/646633. Although the conflicting claims are not identical, they are not patentably distinct from each other because given the totality of the teachings in claims 1-7 and 17-22 of the '633 application, it would have been prima facie obvious to one of ordinary skill in the art to have provided reagents comprising the sets of probes set forth in the rejected claims. For example, claim 5 of the conflicting application sets forth that the probes are full-length probes, and claim 7 sets forth the concentrations of the probes in the solution. Thus, the claims are rejected.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

### **Response to Remarks**

The remarks filed 9/9/05 with the amendment state that the rejections have been overcome by the amendment. However, this is not persuasive.

First, regarding the 102 rejections and the 103 rejections which rely on Meijer et al. are sufficiently broad so as to still encompass cocktails of short oligomers as taught and exemplified by Meijer et al. The claims do not require any structural feature which distinguishes from the cocktails. The probes taught by Meijer et al. meet the functional requirement that they

Art Unit: 1634

“detectably hybridize to the entire full-length genomic sequence” of each HPV type. These probes are capable of hybridizing to the full length sequence of the HPV sequence from which they are each derived, and in fact are meant to do so for detection of target sequence.

Applicant’s previous traversal of the rejection under Nuovo et al. in view of Cox et al. is addressed in the advisory action mailed 7/28/05.

### ***Conclusion***

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Juliet C Switzer whose telephone number is (571) 272-0753. The examiner can normally be reached on Monday, Tuesday, and Thursday, from 9:00 AM until 4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, W. Gary Jones can be reached by calling (571) 272-0745.

The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571)272-0507.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO’s Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of

Art Unit: 1634

the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.



Juliet C. Switzer  
Primary Examiner  
Art Unit 1634

November 8, 2005